Ardelyx Inc. (NASDAQ: ARDX) stock gained by 1.03% in the current market trading session. Ardelyx is dedicated to discovering, developing, and promoting novel first-in-class medications that will improve the lives of people suffering from kidney and cardiorenal illnesses.
>> 7 Top Picks for the Post-Pandemic Economy <<
ARDX stock’ Current Development
The results of Ardelyx’s 52-week Phase 3 PHREEDOM trial have been published in Kidney360, the journal of the American Society of Nephrology.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Mike Raab, president, and chief executive officer of Artily said that the PHREEDOM experiment, a 52-week randomized Phase 3 trial evaluating tenapanor monotherapy, was the third of three Phase 3 trials they performed in the complete investigation of tenapanor for serum phosphorus management in patients on dialysis with chronic kidney disease. The PHREEDOM results show that tenapanor can reduce phosphorus levels significantly while maintaining a level of long-term safety that is comparable to active control.
This research, combined with results from their AMPLIFY trial, demonstrates the critical role that tenapanor, with its new blocking action, can serve in the treatment of hyperphosphatemia in patients on dialysis with serious kidney disease.
Arnold Silva, director of Clinical Research at Boise Kidney and Hypertension Institute, further stated,
As a researcher in this clinical research and an author on this paper, he had the chance to see the influence of tenapanor on serum phosphorus management firsthand and in bulk. He feels that this innovative mechanism therapy will be critical in improving the treatment of hyperphosphatemia in the dialysis patients with CKD. Therapy options have been restricted in this area, and despite treatment response with currently available medications, a significant proportion of patients have phosphorus levels above goal values. Furthermore, whether taken alone or in conjunction with phosphate binders, a one pill twice daily therapy that limits phosphorus absorption has the potential to lessen treatment burden, which will be a substantial advantage to patients.